Last updated on February 2019

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

Brief description of study

TITAN RCC (0216-ASG) is a Phase 2, open-label study of nivolumab monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and pretreated (2nd line), advanced or metastatic renal cell carcinoma (mRCC) subjects with intermediate and high risk disease according to IMDC.

Detailed Study Description

The primary object is to estimate the Objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with International Metastatic RCC Database Consortium (IMDC) intermediate and high risk, advanced Renal cell carcinoma (RCC) with clear cell component

Clinical Study Identifier: NCT02917772

Find a site near you

Start Over

ZNA Middelheim

Antwerpen, Belgium
  Connect »

CHR Verviers

Verviers, Belgium
  Connect »

FN Motol

Praha, Czechia
  Connect »

CHD Vend e

La Roche-Sur-Yon, France
  Connect »

Broomfield Hospital

Chelmsford, United Kingdom
  Connect »

Charing Cross Hospital

London, United Kingdom
  Connect »

Kent Oncology Centre

Maidstone, United Kingdom
  Connect »

Royal Preston Hospital

Preston, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.